Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 5Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 212Leukemia, Myeloid, Acute 178Leukemia 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Myeloproliferative Disorders 62Leukemia, Myelomonocytic, Chronic 61Lymphoma, Non-Hodgkin 48Multiple Myeloma 43Primary Myelofibrosis 41Hodgkin Disease 37Lymphoma 36Blast Crisis 32Leukemia, Lymphocytic, Chronic, B-Cell 29Hematologic Neoplasms 29Polycythemia Vera 26Leukemia, Myeloid, Chronic-Phase 26Leukemia, Myeloid, Accelerated Phase 26Lymphoma, Mantle-Cell 24Thrombocythemia, Essential 23Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 20Burkitt Lymphoma 20Anemia, Refractory, with Excess of Blasts 20Myelodysplastic-Myeloproliferative Diseases 19Recurrence 18Congenital Abnormalities 18Neoplasms, Plasma Cell 16Lymphoma, B-Cell, Marginal Zone 16Lymphoma, Large-Cell, Immunoblastic 15

Interventions

4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Philadelphia Chromosome × Myeloid × Clear all
NCT01602952 2018-08-29

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Il-Yang Pharm. Co., Ltd.

Phase 1/2 Completed
85 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡